Five Clicks Instead of a Quarter Milligram

One in five people in the standard-titration arm of this trial quit because of gastrointestinal side effects. In the arm that climbed more slowly, it was one in fifty — and both groups ended on similar doses with similar blood sugar and weight results.^[1] If that holds up, the schedule printed on the label is costing a substantial number of people their treatment for nothing.

What the two schedules were

One hundred and four people with type 2 diabetes were randomized to either the label’s semaglutide schedule — 0.25 mg, then 0.5 mg, then 1 mg, stepping up every four weeks — or a slower, flexible one, over 26 weeks.

The flexible arm started at 0.0675 mg, which the paper describes as five clicks of the pen’s dose selector dial. That is roughly a quarter of the label’s already-low starting dose. From there it rose by another 0.0675 mg each week, with increases postponed whenever gastrointestinal side effects appeared.

Read the nausea row honestly

That combination is coherent even with the nausea rate itself unresolved. Roughly similar proportions may feel sick, for fewer days, less severely, with the option of pausing the climb — and that is the difference between an unpleasant few months and quitting.

Same destination, gentler road, and nine times as many people still on it.

Why this matters more than most trial results

Almost everything in this field trades benefit against harm: more weight loss, more side effects. This does not. The flexible arm reached comparable doses and comparable results. The cost of the gentler schedule was time, and the return was a large reduction in people abandoning treatment.

Discontinuation is the central problem with these drugs. People stop, and weight comes back — which is the whole subject of what happens when you stop. Anything that keeps people on treatment without costing efficacy is worth more than another percentage point of weight loss.

It also reframes what the label’s starting dose is for. The 0.25 mg step exists to be tolerated rather than to work — and this trial suggests that for a substantial minority, it is not low enough to do that job.

Why this is not a set of instructions

The useful thing to take from it is not a number of clicks. It is that slowing down is a legitimate option with randomized evidence behind it, and that a prescriber can hold a dose or extend the interval — language the labels already contain, in the form of “as tolerated.” Someone struggling with the standard climb has something specific to bring to that conversation now.

The same click-counting technique used as a permanent low dose rather than a slow start is a different practice with a different evidence base, covered in microdosing.

The limits

• It is a pilot. One hundred and four people, described as such by the authors.
• Open-label. Everyone knew which schedule they were on, and expectation affects reported nausea more than most outcomes.
• Type 2 diabetes only, on semaglutide doses up to 1 mg — not the 2.4 mg used for weight management, where the climb is longer and the top dose higher.
• Twenty-six weeks, which covers the titration period and little beyond it.
• The paper carries a published erratum whose content we have not read.